New onset refractory status epilepticus (NORSE) was defined by the International League Against Epilepsy as occurring in patients presenting without a prior diagnosis of epilepsy or other neurological disease, with seizures that persist beyond 24 h. There is still a need to develop new treatment strategies for NORSE, particularly for those patients who are least responsive to conventional medical therapies. We present a case of a young female patient without any medical history presenting with status epilepticus, which was refractory not only to anti-seizure medications and anesthetics, but also to conventional immunomodulatory therapies. After nine weeks of electroclinical seizure activity, the patient responded to two doses of tocilizumab.
|Idioma original||English (US)|
|Número de artículo||100431|
|Publicación||Epilepsy and Behavior Reports|
|Estado||Published - ene 2021|
ASJC Scopus subject areas
- Clinical Neurology
- Behavioral Neuroscience